SCHEMBL2748014

SCHEMBL2748014

COC(=O)c1cccc2cc(Nc3ccnc4cc(OC)c(OC)cc34)ccc12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 15/20 0.75
▸ EGFR P00533 4/20 0.61
▸ GAK O14976 3/20 0.58
▸ PDGFRA P16234 1/20 0.57
▸ LCK P06239 8/20 0.54
▸ AURKA O14965 7/20 0.54
▸ MET P08581 7/20 0.54
▸ TEK Q02763 7/20 0.54
▸ AURKB Q96GD4 6/20 0.54
▸ ABL1 P00519 2/20 0.54
▸ BMPR1B O00238 1/20 0.54
▸ EPHB6 O15197 1/20 0.54
▸ RIPK2 O43353 1/20 0.54
▸ SRC P12931 1/20 0.54
▸ EPHA1 P21709 1/20 0.54
▸ EPHA8 P29322 1/20 0.54
▸ ACVR1 Q04771 1/20 0.54
▸ MAP2K5 Q13163 1/20 0.54
▸ COQ8A Q8NI60 1/20 0.54
▸ NLK Q9UBE8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748802 0.86 KDR (1.00) KDRLCKAURKAMETTEK
SCHEMBL4548960 0.84 KDR (0.81) KDRPDGFRALCKAURKAMET
SCHEMBL4548961 0.83 KDR (0.73) KDREGFRLCKAURKAMET
SCHEMBL2746962 0.83 KDR (0.62) KDREGFRGAKLCKRIPK2
SCHEMBL4548886 0.81 KDR (0.61) KDREGFRGAKPDGFRALCK
SCHEMBL5753165 0.80 KDR (0.58) KDREGFRLCKAURKAAURKB
SCHEMBL2614561 0.80 KDR (0.74) KDREGFRGAKLCKAURKA
SCHEMBL2614562 0.79 KDR (0.63) KDREGFRGAKLCKAURKA
SCHEMBL2748016 0.78 EGFR (0.60) KDREGFRGAKPDGFRALCK
SCHEMBL2614552 0.78 KDR (0.61) KDRLCKAURKAMETTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 — — US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 — — US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 — — US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 — — US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 — — EP disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885EGFR 129/4885GAK 1644/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885EGFR 129/4885GAK 1644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback